东富龙收盘下跌1.15%，滚动市盈率61.39倍，总市值91.82亿元

Group 1 - The core business of the company is to provide pharmaceutical process, core equipment, and overall engineering solutions for global pharmaceutical enterprises [1] - The main product segments include bioprocessing, formulation, overall engineering solutions, and food equipment engineering [1] - As of March 31, 2025, the company had 31,365 shareholders, a decrease of 2,055 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - The company's latest quarterly report for Q1 2025 shows a revenue of 1.137 billion yuan, a year-on-year increase of 2.58%, and a net profit of 20.1326 million yuan, a year-on-year decrease of 68.87%, with a gross profit margin of 24.45% [1] - The company's current price-to-earnings (PE) ratio is 61.39, compared to the industry average of 50.97 and the industry median of 36.67, ranking 94th in the industry [2] - The total market capitalization of the company is 9.182 billion yuan [2]